Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous NKG2D CAR-expressing T lymphocytes ASP2802

A preparation of autologous T lymphocytes that are genetically modified to express a chimeric antigen receptor (CAR) for a modified and inactivated form of the type II transmembrane protein human natural-killer group 2, member D receptor protein (NKG2D; KLRK1), that can be used for potential immunostimulating and antineoplastic activities upon activation in vivo. Upon infusion back into the patient, autologous NKG2D CAR-expressing T lymphocytes ASP2802 are inert. Upon subsequent administration of MA-20 (ASP101G; MicAbody), a bispecific adaptor molecule composed of an anti-CD20 antibody linked to a UL16-binding protein (ULBP) 2 ligand, the anti-CD20 antibody moiety of MA-20 targets and binds to CD20-expressing tumor cells and the ULBP2 ligand targets and binds to the NKG2D CAR moiety of the convertible CAR T-cells ASP2802, thereby activating the inactivated CAR T cells, which induce selective toxicity in and lysis of CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.
Synonym:convertible CAR T cells ASP2802
Code name:ASP 2802
ASP-2802
ASP2802
Search NCI's Drug Dictionary